ABSTRACT
Objective:
We aimed at determining whether there was a relationship between the fetus weight and biochemical markers (hCG, MSAFP, and unconjugateed estriol) results that were studied in the maternal serum during the aneuploidy screening in the second trimester.
Methods:
In our study, 425 pregnant women who had completed their triple scan tests and who gave mature birth in our Ege Obstetrics and Birth Training and Research Hospital were retrospectively examined. The babies were divided into groups that were suitable to 5%, 10%, 50%, 90%, and 95% according to their birth weight. The number of patients in the groups was 26, 63, 359, 27, and 8, respectively. The babies who were suitable for 50% were the control group. The results of hCG, AFP, and E3, which were used for the triple scan test in the second trimester, were found in the archive of our hospital. Babies who had fetal anomalies, pregnant women with gestational diabetes and hypertension, pregnant women who had chronical diseases, and those who smoked were excluded from the study.
Results:
In this study, the average birth weight of babies who were over 2 MoM for hCG 2963.75 g difference was found statistically meaningful. However, the birth weight of 2963.75 g was suitable to 10%–50%. When the average birth weight of the babies who had less than 0.5 MoM for AFP 3032.50 g was compared with the control group, there was a statistically meaningful difference (p=0.009), but the average birth weight of this group was also found suitable nearly to 50%. While comparing the group who had more than 2 MoM for AFP with the group who had less than 2 MoM for hCG, no meaningful statistical difference was found. While comparing the groups who had less than 0,5 MoM for uE3 and more than 1.5 MoM with the control group, no statistically meaningful difference was found.
Conclusion:
It is observed that the power of the biochemical scan tests to predict the fetal weight in the first and second trimester was low. There is a requirement to combine more than one abnormal test to study wider populations and to identify new tests. (JAREM 2016; 6: 19-23)